TOP 10
Longevity Breakthrough Awards 2026

Participant Guide

Celebrating Innovation in Longevity Medicine

APAC Healthy Longevity International Summit | Hong Kong | October 1-4, 2026

For companies, startups, clinics, translational teams and innovators building the future of evidence-based longevity medicine.

OPEN FOR NOMINATIONS	NOMINATION DEADLINE	SUMMIT EVENT	LOCATION
May 1, 2026	**August 15, 2026**	**October 1-4, 2026**	**Hong Kong**

Participant-facing note

This guide describes the expected benefits, categories, criteria and participant journey for the 2026 TOP 10 Longevity Breakthrough Awards.

Clinical use, market deployment, regulatory approval, insurance integration and commercial partnerships are subject to applicable authority approvals, safety review, contracts and local requirements.

Contact: top10@longevityawards.org

Contents

Core promise

The Awards are designed to identify scientifically credible, clinically relevant and commercially feasible innovations in longevity medicine - and to connect the strongest teams with Asia-Pacific validation, localization, clinical, investor and business opportunities.

1. Competition overview

The TOP 10 Longevity Breakthrough Awards 2026 recognize the most promising innovations in longevity medicine: solutions that can meaningfully improve human healthspan, resilience, function or longevity-related biomarkers.

The competition focuses on industry-led solutions with human evidence, real novelty and a credible pathway to deployment. It is not designed to reward hype, general wellness claims, simple repackaging or disease-treatment products that do not clearly address healthspan or biomarker improvement.

Program element	Details
Main focus	Longevity medicine: validated products, technologies, interventions and decision-support tools that improve health, biomarkers and real-world healthspan potential.
Audience	Companies, startups, clinics, translational research teams, clinical product teams, diagnostics developers, AI companies and device innovators.
Recognition pathway	Screening, semifinal detailed evaluation, jury review, finalist recognition, presentation opportunities and Awards Gala celebration.
Summit context	APAC Healthy Longevity International Summit, Hong Kong, October 1-4, 2026.

Contact: top10@longevityawards.org

2. Why participate: the participant value proposition

Participation is designed to provide more than a trophy. The Awards act as a platform for recognition, validation, clinical translation, market access and commercial matchmaking across the Asia-Pacific longevity ecosystem.

What participants may gain	Why it matters
Worldwide recognition	Awardees and finalists gain visibility as part of an evidence-oriented longevity medicine platform associated with the APAC Healthy Longevity International Summit in Hong Kong. Recognition can support credibility with clinics, investors, collaborators, media and regional partners.
Asia market access and localization	The program can help selected teams explore market accessibility and localization pathways across Asia, including Mainland China, Hong Kong, Macau, Japan, South Korea, Thailand, Malaysia and other regional markets.
Scientific committee validation	Startup products and services that enter detailed evaluation are reviewed by the scientific committee. For products that satisfy evidence, safety and regulatory expectations, this can support consideration by participating longevity clinics and validation partners.
Access to A&V Centre programs	Participants may be considered for Acceleration & Validation Centre programs that support clinical validation, real-world evidence generation, localization planning and regional partner engagement.
Clinical trial and research facility pathways	The A&V Centre can help suitable awardees explore clinical trial sites, research facilities and study pathways in Hong Kong, Mainland China and the broader APAC region, subject to feasibility and approvals.
Collaborator and investor interest	Finalists and awardees can attract attention from clinicians, research groups, investors, regional distributors, strategic partners, pharmaceutical companies, medical device companies and insurers.
Awards Gala & Celebration	Participants join the Awards Gala & Celebration during the APAC Healthy Longevity International Summit, creating a high-visibility networking moment with the longevity medicine community. Participants will be provided a space for their presentations.
Semifinalist Certificate	All submissions accepted into the semifinal detailed evaluation will receive a Semifinalist Certificate, providing a formal credential even before final TOP 10 selection.

3. Asia market access, validation and localization pathways

Asia is a priority region for longevity medicine commercialization. The Awards are designed to help credible innovations move from international visibility into practical regional conversations with clinics, research sites, local businesses, investors and market-entry partners.

3.1 Market accessibility across Asia

Selected companies may benefit from program visibility and introductions across a broad Asia-Pacific footprint. This includes Mainland China, Hong Kong, Macau, Japan, South Korea, Thailand, Malaysia and other regional markets where longevity clinics, medical groups, consumer health networks and healthcare businesses are evaluating evidence-based longevity products.

- **Market positioning:** Participants can clarify how their solution fits local patient, consumer, clinic and payer needs.
- **Localization support:** Selected teams may receive feedback on language, evidence packaging, clinical workflow fit, regional business model, authority expectations and safety documentation.
- **Commercial readiness:** The program emphasizes evidence, novelty, safety and feasibility so that products can be presented credibly to partners rather than relying on unsupported claims.

3.2 Scientific committee validation and clinic adoption pathways

For startups, independent scientific review can be especially valuable. Products that pass detailed evaluation can use the result as a credibility signal when speaking with clinics, strategic partners and investors.

Clinic use pathway

Scientific review: Startup products entering semifinal evaluation are assessed by the scientific committee for evidence quality, novelty, healthspan or biomarker relevance, safety and feasibility.

Clinic consideration: Products with sufficient evidence and required safety or authority approvals may be considered for use, piloting or further validation by participating clinics and research partners.

No shortcut around approvals: The Awards do not replace regulatory, ethics, authority, safety or medical governance review. Any clinical use remains subject to the requirements of the relevant market and clinical site.

3.3 Clinical trial sites and research facilities

The A&V Centre is intended to support evidence generation by connecting suitable products and technologies with clinical trial sites, research facilities, clinical investigators and real-world data pathways. This may include protocol refinement, endpoint discussion, biomarker strategy, site feasibility and regional study planning.

Case study: Circulate Health

Organizer-provided case example: the A&V Centre is working with Circulate Health, a 2025 TOP 10 awardee, to conduct clinical trials through pathways involving both Hong Kong and Mainland China.

This example illustrates the intended role of the Awards and A&V Centre: helping credible awardees move from recognition to structured clinical validation and regional localization.

3.4 Business and payer ecosystem interest

The Awards also create visibility with local Asian businesses that are actively searching for high-quality, safety-reviewed longevity products and services. Potential stakeholders include pharmaceutical companies, medical device companies, clinic networks, distributors, digital health companies and insurance groups.

Commercial access example: Ping An

Organizer-provided example: the A&V Centre is working with Ping An, China insurance giant with 11 longevity service centers in China, to identify high-quality longevity products and services for its customers.

Products and services considered for customer or clinic deployment must satisfy applicable safety, authority approval, regulatory, contractual and quality requirements.

4. Awards Gala, recognition and certificates

Recognition is built into multiple stages of the competition, not only the final winner announcement.

Recognition opportunity	Description
Semifinalist Certificate	Every applicant accepted into the semifinal detailed evaluation will receive a formal Semifinalist Certificate. This recognizes that the submission passed initial screening and entered detailed review.
TOP 10 Finalist recognition	Finalists selected by the jury will be recognized as part of the TOP 10 Longevity Breakthrough Awards 2026 cohort.

Contact: top10@longevityawards.org

Recognition opportunity	Description
Awards Gala & Celebration	Finalists and winners will be celebrated during the APAC Healthy Longevity International Summit in Hong Kong. The Gala is designed as a high-visibility moment for networking, press, investor and partner conversations.
Conference Presentations	Participants will be provided with an expo area (poster type) and TOP10 will be eligible to present their solutions at sessions.
Post-award visibility	Selected teams may be featured in award communications, summit materials, winner profiles, partner discussions and follow-up opportunities, subject to organizer confirmation and participant permissions.

Awards Gala & Celebration schedule: APAC Healthy Longevity International Summit schedule

5. Who should apply

The Awards are best suited to companies and translational teams that can show human evidence, real novelty and a path to practical use in longevity medicine.

Strong fit	Usually not a fit
Companies or startups with first human data, pilot studies, case series, clinical trial summaries, published papers or robust real-world evidence.	Purely theoretical ideas, animal-only results or preclinical discoveries with no human data.
Diagnostics, therapies, devices, supplements or AI systems designed to improve healthspan, resilience, function or biomarkers.	Products focused only on disease treatment without a clear healthspan, biomarker or longevity medicine rationale.
Products with a realistic path to clinic, consumer, payer, research or partner deployment within roughly 1 year.	Simple repackaging, reformulation, compounding, branding changes or distribution-only businesses without real scientific novelty.
Teams prepared to submit evidence, safety information, product details, commercialization plans and supporting documents.	Marketing-led products that cannot provide clinical evidence, safety rationale or credible mechanism of action.

6. Award categories

Applicants should select the primary category that best matches the solution. If a product crosses categories, choose the main use case and explain secondary relevance in the submission.

Category	Scope	Strong submission should show
Health Diagnostics	Devices, software, biomarker analysis and related diagnostic solutions that improve measurement, interpretation or longitudinal tracking of health and longevity biomarkers.	Validated biomarkers, test performance, usability, repeatability, clinical workflow fit, human data, data interpretation quality and actionable relevance.
Advanced Therapeutics / Therapies	Innovative therapies with a profound effect on health or biomarker improvement, focused on longevity medicine rather than disease treatment alone.	Human evidence of biomarker or functional improvement, mechanism of action, safety data, dosing or treatment protocol, durability of effect and near-term deployment feasibility.
Advanced Supplements	Novel supplements or nutraceutical interventions with clear scientific differentiation. Simple repackaging, reformulation or compounding does not qualify.	Ingredient novelty, mechanism, formulation rationale, clinical or human data, safety profile, manufacturing quality and clear differentiation from existing products.

Contact: top10@longevityawards.org

Category	Scope	Strong submission should show
Therapeutic Devices	Device-based interventions with measurable effect on health or biomarker improvement, focused on longevity medicine rather than disease treatment alone.	Device safety, user protocol, human outcomes, biomarker or functional improvements, regulatory status, usability, reliability and clinic or home-use deployment path.
Medical and Assisting AI (Augmented Intelligence)	AI systems that augment clinical judgment, diagnostics, monitoring, personalization, decision support or care coordination in longevity medicine.	Clinical validation, model performance, explainability, safety guardrails, workflow integration, clinician oversight, data governance and measurable impact on decisions or outcomes.

7. Eligibility and evidence requirements

The Awards prioritize real-world translation. Applicants should prepare a complete evidence package before submission.

Requirement	Description
Industry-only focus	Open to companies, startups, clinics and translational research teams. Academic spin-offs are welcome when there is a clear plan to deliver the solution to patients, clinics, consumers or partners.
Human evidence required	Solutions must have reached at least first human results. Evidence may include papers, studies, trial summaries, case series, pilot results or equivalent human data.
Evidence must be submitted	The submission should include direct evidence files, study references, summaries, protocols, safety data, product documentation and supporting materials.
Real novelty required	The solution must demonstrate genuine scientific, technical, clinical or product novelty. Simple repackaging, compounding or branding-only changes are not eligible.
Commercial feasibility within 1 year	Applicants should show a credible pathway to deployment, partnership, piloting, validation, licensing or market entry within approximately 1 year.
Safety and authority readiness	Applicants should identify relevant safety information, regulatory status, authority requirements and quality controls for target markets.

8. Judging criteria

Submissions will be evaluated by an independent panel of judges and/or scientific reviewers using evidence-oriented criteria. Applicants should organize their submissions so that reviewers can easily find the information below.

Criterion	What judges evaluate	What to provide
Clinical Evidence	Quality, strength and relevance of submitted human evidence.	Papers, trial summaries, clinical datasets, case series, human biomarker results, real-world evidence and explanation of endpoints.
Innovation and Real Novelty	Scientific merit, technical differentiation and novelty beyond repackaging or compounding.	Mechanism of action, novel formulation or device design, unique dataset, IP position, product architecture and comparison with alternatives.
Impact on Healthspan and Biomarkers	Meaningful improvement in health, resilience, function or longevity-related biomarkers.	Pre/post biomarker data, functional outcomes, effect size, durability, target population and relevance to longevity medicine.
Commercial Feasibility within 1 Year	Practical readiness for near-term deployment, piloting or commercial partnership.	Manufacturing plan, regulatory pathway, deployment model, pricing, partnerships, clinic workflow, reimbursement or payer logic.

Criterion	What judges evaluate	What to provide
Scalability and Accessibility	Potential for broad implementation and access beyond a small elite user group.	Cost model, training needs, infrastructure requirements, target countries, distribution strategy and localization plan.
Safety and Ethical Standards	Safety profile, responsible use, ethical sourcing, data protection and patient or customer protection.	Safety studies, adverse-event data, contraindications, consent model, data governance, quality management and authority status.
Team and Execution Capability	Credibility, domain expertise, operational readiness and ability to deliver.	Team bios, advisors, clinical partners, prior studies, fundraising or revenue traction, manufacturing or implementation experience.

9. What happens after submission

The competition process is designed to be rigorous, fair and practical for a small annual awards program.

Step	Description
1. Submission	Applicants submit the category, company and product details, evidence summary, supporting documents and contact information.
2. Completeness check	The awards team may request additions if required information or evidence is missing.
3. Initial eligibility screening	Submissions are screened for category fit, human evidence, novelty, safety concerns, commercial feasibility and basic completeness.
4. Semifinal detailed evaluation	Accepted submissions enter detailed evaluation. All submissions accepted into this stage receive a Semifinalist Certificate.
5. Jury review	Judges review detailed materials and score submissions against the award criteria. Conflicts of interest should be disclosed and managed.
6. TOP 10 selection	The strongest submissions are selected as TOP 10 finalists based on scientific credibility, healthspan relevance, feasibility and overall award fit.
7. Summit recognition	Finalists and winners are recognized through summit activities, presentations, the Awards Gala and follow-up communications.
8. Post-award pathways	Selected awardees may be invited to explore A&V Centre programs, clinical validation, regional localization, investor introductions or partner discussions.

10. Practical guidance for a strong application

Strong submissions make it easy for reviewers to understand the product, evidence, novelty, safety profile and commercialization path.

Recommended submission package

- **One-page executive summary:** problem, product, target user, category, evidence, impact and why it is a longevity medicine breakthrough.
- **Evidence summary:** published papers, clinical reports, trial summaries, case series, human data and biomarker results.
- **Mechanism and novelty statement:** what is genuinely new and why the product is more than repackaging, compounding or branding.
- **Safety and regulatory summary:** known risks, contraindications, safety studies, authority status and quality controls.

- **Commercialization plan:** target markets, clinic workflow, partner strategy, manufacturing or scaling plan and feasibility within 1 year.
- **Asia localization plan:** priority markets such as Mainland China, Hong Kong, Macau, Japan, South Korea, Thailand, Malaysia or other Asia-Pacific countries; expected localization needs and partner profile.

Common weaknesses to avoid

- Submitting only a pitch deck with marketing claims and no human data.
- Claiming longevity benefits without explaining biomarkers, function, endpoints or clinical relevance.
- Using disease-treatment evidence only, without showing a clear healthspan or biomarker improvement rationale.
- Presenting a supplement that is only a repackaged or compounded version of existing ingredients.
- Ignoring safety, contraindications, data privacy, regulatory status or clinical governance requirements.
- Failing to explain how the product could be deployed, validated or commercialized within 1 year.

11. Important participant notes

Topic	Participant note
Awards and certificates	A Semifinalist Certificate confirms acceptance into detailed semifinal evaluation. TOP 10 Finalist and winner recognition is determined by the awards process and jury review.
No automatic clinical use	Scientific committee validation can support credibility and clinic consideration, but it does not automatically authorize clinical use. Use in clinics requires safety review, authority approvals, site acceptance and applicable regulatory compliance.
No guaranteed investment or partnership	The Awards can create visibility with investors, collaborators, clinics and local businesses, but do not guarantee investment, distribution, insurance adoption or commercial contracts.
Authority approval and safety	Products considered for clinic, customer, payer or partner deployment must satisfy relevant safety, regulatory, ethics, authority and quality requirements in each target market.
Confidentiality	Applicants should clearly mark confidential documents. Public profiles, press materials or winner summaries should be approved by the participant before release.
Organizer-provided examples	Circulate Health and Ping An examples in this guide are included as organizer-provided illustrations of the intended A&V Centre pathway and should be confirmed with the awards team before public use in external marketing materials.

Final message to applicants

If your solution has human evidence, real novelty and a credible path to improving healthspan or longevity-related biomarkers, the TOP 10 Longevity Breakthrough Awards can help you gain recognition, strengthen scientific credibility, and open conversations with clinics, researchers, investors and commercial partners across Asia.

Contact: top10@longevityawards.org

The TOP 10 Longevity Breakthrough Awards 2026 recognize clinically grounded innovations that can improve healthspan, biomarkers and the future practice of longevity medicine.

Participants gain global visibility, access to APLMS Acceleration & Validation Centre pathways, opportunities for Asia-Pacific localization, potential interest from investors and strategic partners, and recognition during the Awards Gala & Celebration at the APAC Longevity Medicine Summit in Hong Kong.

The program offers special value for startups seeking scientific committee validation, clinic adoption pathways, clinical trial or research facility connections, and commercial exposure across markets such as Mainland China, Hong Kong, Macau, Japan, South Korea, Thailand and Malaysia. Products considered for clinical or customer deployment must satisfy applicable safety and authority requirements.

All accepted semifinalists receive a Semifinalist Certificate. Finalists and awardees may be invited to explore further validation, localization, clinical research and business development opportunities through the A&V Centre and the broader APLMS network.

Contact: top10@longevityawards.org